You are subscribed to the FormularyWatch.

Formulary

eNewsletter Subscribe

January 28, 2015

Web Version  | Share with a colleague

Facebook Like Twitter Tweet

Today's Headlines

[BLOG]: Potential impact of novel pipeline therapies entering the uncharted celiac disease market

The current global celiac disease market is naïve, with no disease-specific drugs available to date. Although following a gluten-free diet appears to be a straightforward process, it can actually be problematic and inconvenient due to the presence of gluten in most foods, which means there is an immediate need for pharmacological intervention in celiac disease patients. » Find out what's in the pipeline

FDA approves secukinumab for moderate-to-severe plaque psoriasis

FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of moderate-to-severe plaque psoriasis. » Read more on plaque psoriasis

Continuing Education

MTM opportunities in caring for the patient with cardiovascular disease

This month's CE activity is the last unit of a year-long CPE series, Medication Therapy Management Considerations for Adult Patients with Cardiovascular Disease. Running from February 2014 through January 2015, the series enables pharmacists to earn up to 24 hours of CPE credit with 12 monthly knowledge-based activities from the University of Connecticut School of Pharmacy and Drug Topics.

The goal of this month's activity is to empower pharmacists to engage patients with cardiovascular disease in the practices of self-management.

To read and print the article with TEST QUESTIONS, click here. To proceed to the online exams and earn up to 2 CPE credits, click here to log in with the session code 15DT01-JKF33.


Announcement: Our CE activities have moved to a new learning management system to better serve you. The login to the Online CE Center is https://web2.uconn.edu/pharmacyce/login.php. All current user registration information has been uploaded for your convenience. Current users do not need to register. To review your registration page to ensure the data is up to date or to register, go to https://web2.uconn.edu/pharmacyce/program_register.php. For a full list of courses, go to http://pharmacy.uconn.edu/academics/ce/drug-topics-and-uconn-ce/

EDITOR'S PICK

Myalept: Drugs in Perspective

Myalept (metreleptin) was granted a priority review and was FDA approved as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired lipodystrophy. » Details

 

RELATED ARTICLES

[BLOG]: Pipeline advancement responsible for upturn in global pharma R&D

Secukinumab clears skin in psoriasis patients: Studies

RESOURCES

Latest Clinical News

Powered by Modern Medicine Advanstar Medical Communications Group